BGI
In Brief This Week: Pierian, PerkinElmer, Decode Health, Quest, Nucleix, More
News items for the week of Oct. 17, 2022.
BGI Gets CE-IVD Mark for Thalassemia Test
The test detects mutations causing alpha- and beta-thalassemia, heritable disorders characterized by low hemoglobin levels.
BGI Genomics Program Seeks to Validate Signatera Test for Colorectal Cancer Patients in China
Premium
The molecular residual disease test from Natera was first made available to biopharmaceutical customers and clinicians across China in June.
Although demand for the firm's COVID-19 testing declined in H1, other diagnostic areas and its international business have grown.
BGI Genomics H1 Revenues Fall 11 Percent on COVID-19 Testing Decline
The firm's other businesses saw steady growth, with cancer prevention revenues up 94 percent and infection prevention and control revenues more than tripling.